Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

INTI FERNANDEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1659461101
CMS profile
75387
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$104.22

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $104.22 5

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $23.45 1
AstraZeneca Pharmaceuticals LP $22.50 1
Amgen Inc. $20.67 1
Novo Nordisk Inc $20.46 1
PFIZER INC. $17.14 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

INTI FERNANDEZ

NPI 1659461101 · CMS profile ID 75387

Allopathic & Osteopathic Physicians / General Practice

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $104.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $20.6709/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228351952 CMS
PFIZER INC. $17.1406/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229315223 CMS
Merck Sharp & Dohme LLC $23.4504/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238150586 CMS
Novo Nordisk Inc $20.4603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189129401 CMS
AstraZeneca Pharmaceuticals LP $22.5003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206676647 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.06 4
PY2020 $15.80 1
PY2021 $68.75 4
PY2022 $37.69 2
PY2023 $109.38 6
PY2024 $406.19 11
PY2025 $104.22 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $247,458.00 56
PY2024 Principal investigator $394,912.46 60
PY2023 Principal investigator $216,893.52 51
PY2022 Principal investigator $150,151.52 34
PY2021 Principal investigator $179,866.77 30
PY2020 Principal investigator $179,109.45 79
PY2019 Principal investigator $44,348.58 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $3,913.56 12/31/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721315651
Principal investigator 1 Allergan, Inc. $5,341.64 12/31/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721315777
Principal investigator 1 Allergan, Inc. $877.00 12/31/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Pediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study No dispute reported 06/30/2026 721316379
Principal investigator 1 Allergan, Inc. $12,346.10 12/31/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721317437
Principal investigator 1 Allergan, Inc. $5,901.65 12/31/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721317587
Principal investigator 1 Allergan, Inc. $86.00 12/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721313649
Principal investigator 1 Allergan, Inc. $14,991.00 12/15/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721313125
Principal investigator 1 Allergan, Inc. $3,990.00 12/15/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721313229
Principal investigator 1 Allergan, Inc. $315.00 12/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721310321
Principal investigator 1 Allergan, Inc. $315.00 12/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721310353
Principal investigator 1 Allergan, Inc. $14,257.60 11/18/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721308717
Principal investigator 1 Allergan, Inc. $86.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721306717
Principal investigator 1 Allergan, Inc. $315.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721306739
Principal investigator 1 Allergan, Inc. $371.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721306755
Principal investigator 1 Allergan, Inc. $1,939.90 10/14/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721302667
Principal investigator 1 Allergan, Inc. $12,302.50 10/13/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721302279
Principal investigator 1 Allergan, Inc. $700.00 10/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721301841
Principal investigator 1 Allergan, Inc. $14,307.95 09/16/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721297897
Principal investigator 1 Allergan, Inc. $6,822.90 09/16/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721297951
Principal investigator 1 Allergan, Inc. $86.00 09/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721296761
Principal investigator 1 Allergan, Inc. $86.00 09/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721296263
Principal investigator 1 Allergan, Inc. $86.00 09/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721296365
Principal investigator 1 Allergan, Inc. $86.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721294999
Principal investigator 1 Allergan, Inc. $86.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721293803
Principal investigator 1 Allergan, Inc. $8,507.25 08/14/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721290411
Principal investigator 1 Allergan, Inc. $86.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721289235
Principal investigator 1 Allergan, Inc. $700.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721289399
Principal investigator 1 Allergan, Inc. $86.00 08/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721288267
Principal investigator 1 Allergan, Inc. $86.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721287733
Principal investigator 1 Allergan, Inc. $700.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721287973
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286759
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286911
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721287083
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721287127
Principal investigator 1 Allergan, Inc. $86.00 07/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721285861
Principal investigator 1 Allergan, Inc. $13,021.65 07/17/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721285089
Principal investigator 1 Allergan, Inc. $86.00 07/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721283375
Principal investigator 1 Allergan, Inc. $2,500.00 07/06/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721282635
Principal investigator 1 Allergan, Inc. $4,446.00 06/15/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721279661
Principal investigator 1 Allergan, Inc. $1,736.60 05/13/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721274911
Principal investigator 1 Allergan, Inc. $7,771.95 04/14/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721270127
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721267071
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267209
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267259
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721267469
Principal investigator 1 Allergan, Inc. $86.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721264809
Principal investigator 1 Allergan, Inc. $11,891.15 03/16/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721264471
Principal investigator 1 Allergan, Inc. $86.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721263249
Principal investigator 1 Allergan, Inc. $86.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721263435
Principal investigator 1 Allergan, Inc. $2,500.00 03/11/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721263121
Principal investigator 1 Allergan, Inc. $8,000.00 03/11/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721263183
Principal investigator 1 Allergan, Inc. $86.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721262613
Principal investigator 1 Allergan, Inc. $86.00 03/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721262227
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721259695
Principal investigator 1 Allergan, Inc. $304.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721260149
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721260609
Principal investigator 1 Allergan, Inc. $86.00 02/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721258517
Principal investigator 1 Allergan, Inc. $1,691.95 02/14/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721257623
Principal investigator 1 Allergan, Inc. $304.00 02/13/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721256543
Principal investigator 1 Allergan, Inc. $8,000.00 02/10/2020 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER CORP
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721256247
Principal investigator 1 Allergan, Inc. $346.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721255623
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721250905
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721251489
Principal investigator 1 Allergan, Inc. $315.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721251547
Principal investigator 1 Allergan, Inc. $882.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721252489
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721252499
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721253321
Principal investigator 1 Allergan, Inc. $315.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253433
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253613
Principal investigator 1 Allergan, Inc. $315.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253651
Principal investigator 1 Allergan, Inc. $413.10 01/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721250299
Principal investigator 1 Allergan, Inc. $86.00 01/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721249151
Principal investigator 1 Allergan, Inc. $86.00 01/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721249329
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721245971
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246177
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246519
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246797
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721247101
Principal investigator 1 Allergan, Inc. $700.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721247137